Zalicus to Present at AACR 2014 Annual Meeting

  Zalicus to Present at AACR 2014 Annual Meeting

       Zalicus and Collaborators Eisai and Sanofi Leverage Combination
  High-Throughput Screening Platform to Evaluate Combination Drug Synergies

AACR Annual Meeting 2014

Business Wire

CAMBRIDGE, Mass. -- April 1, 2014

Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced that a poster developed in collaboration with colleagues from
Eisai Inc. and a podium presentation with collaborators from Sanofi will be
given at the American Association for Cancer Research (AACR) 2014 Annual
Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical
data, which were generated in separate studies by leveraging the Zalicus
combination High-throughput screening (cHTS™) technology platform, demonstrate
the potential to identify (or highlight) synergistic activity of the Eisai
nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through
drug combinations.

Presentations:

  *(Abstract #1698): Monday, April 7, 2014, 8:00 a.m. – 12:00 p.m. PT,
    “Identification of drugs with eribulin combinatorial activity that kill
    both eribulin-sensitive and eribulin-insensitive tumor cells,” T. Uenaka ^
    et. al., Hall A-E, Poster Section 29, San Diego Convention Center.
  *(Abstract #4765): Tuesday, April 8, 2014, 3:05 p.m. – 3:20 p.m. PT, “Drug
    synergies observed for antibody and toxin components of SAR3419 ADC
    contribute to overall conjugate efficacy and can be combination drug or
    tumor cell line dependent,” R. J. Rickles, et. al., Session: Novel
    Biologics as Targeted Cancer Therapy, Room 5, San Diego Convention Center.

“These data demonstrate the power of our cHTS technology to rapidly screen
drug combinations across multiple cellular assays to identify synergistic
activity,” said Mark H. N. Corrigan, M.D., President and CEO of Zalicus. “By
leveraging our combination High-Throughput Screening technology, we are able
to provide value to our collaborators’ programs.”

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain and has entered into multiple revenue-generating collaborations
with large pharmaceutical companies relating to other products, product
candidates and drug discovery technologies. Zalicus applies its expertise in
the discovery and development of selective ion channel modulators and its
combination high throughput screening capabilities to discover innovative
therapeutics for itself and its collaborators in the areas of pain and
oncology. To learn more about Zalicus, please visit www.zalicus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus and
its combination drug discovery technology, cHTS, and its financial condition,
results of operations, and other business plans. These forward-looking
statements about future expectations, plans, objectives and prospects of
Zalicus and its product candidates may be identified by words like "believe,"
"expect," "may," "will," "should," "seek," “plan,” “project” or “could” and
similar expressions and involve significant risks, uncertainties and
assumptions, including risks related to Zalicus’s ability to identify drug
combinations with synergistic activity or its collaborators willingness to
engage Zalicus for these services, the development of its collaborators’
product candidates, Zalicus’s ability to obtain additional financing or
funding for its research and development, and those other risks that can be
found in the "Risk Factors" section of Zalicus' annual report on Form 10-K on
file with the Securities and Exchange Commission and the other reports that
Zalicus periodically files with the Securities and Exchange Commission. Actual
results may differ materially from those Zalicus contemplated by these
forward-looking statements. These forward-looking statements reflect
management’s current views and Zalicus does not undertake to update any of
these forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release except as required by
law.

(c) 2014 Zalicus Inc. All rights reserved.

Contact:

Zalicus Inc.
Justin Renz, 617-301-7575
CFO
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com
 
Press spacebar to pause and continue. Press esc to stop.